Patents by Inventor John C. Chabala

John C. Chabala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040023996
    Abstract: Quinazolinones of formulae (a, b, c and d) are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
    Type: Application
    Filed: August 15, 2003
    Publication date: February 5, 2004
    Inventors: Jeffrey T. Finer, Gustave Bergnes, Bainian Feng, Whitney W. Smith, John C. Chabala, David J. Morgans Jr
  • Patent number: 6630479
    Abstract: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: October 7, 2003
    Assignee: Cytokinetics, Inc.
    Inventors: Jeffrey T. Finer, Gustave Bergnes, Whitney W. Smith, John C. Chabala, Bainian Feng
  • Patent number: 6562831
    Abstract: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: May 13, 2003
    Assignee: Cytokinetics, Inc.
    Inventors: Jeffrey T. Finer, Gustave Bergnes, Whitney W. Smith, John C. Chabala, Bainian Feng
  • Patent number: 6545004
    Abstract: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: April 8, 2003
    Assignee: Cytokinetics, Inc.
    Inventors: Jeffrey T. Finer, Gustave Bergnes, Whitney W. Smith, John C. Chabala, Bainian Feng
  • Patent number: 5140030
    Abstract: Disclosed are 2-aza-substituted 1-carbadethiapen-2-em-3-carboxylic acids. I, where the generic 2-aza group includes azido, acylamino, amino, alkylamino, dialkylamino, triazolyl, triazolinyl, aziridinyl, and their pharmaceutically acceptable salt, ester, anhydride and amide derivatives which are useful as antibiotics. Also disclosed are processes for the preparation of I from the known, appropriately substituted bicyclic keto ester II via the 2-azido central intermediate III: ##STR1## wherein R.sup.16 is H or CH.sub.3, preferably beta-methyl; R.sup.6, and R.sup.7 are independently hydrogen, linear, branched or cyclic C.sub.1 -C.sub.5 alkyl, which can be substituted with fluoro, hydroxy, protected hydroxy, sulfoxy, amino, protected amino, wherein R.sup.6 and R.sup.7 taken together can also be C.sub.2 -C.sub.4 alkylidene, similarly substituted; with the proviso that both R.sup.6 and R.sup.7 are not unsubstituted alkyl, R.sup.1 and R.sup.
    Type: Grant
    Filed: August 16, 1990
    Date of Patent: August 18, 1992
    Assignee: Merck
    Inventors: Burton G. Christensen, Ronald W. Ratcliffe, John C. Chabala
  • Patent number: 5132463
    Abstract: Novel 1,3-Diaryl cyclopentanes of the following general formula were prepared. ##STR1## These compounds were found to have potent and specific PAF (Platelet Activating Factor) antagonistic activities and as such useful in the treatment or amelioration of various diseases or disorders mediated by the PAF, for example, hypotension, inflammation, nephritis, stroke and other cardiovascular disorders, asthma, allergic and skin diseases, peptic or stomach ulcer, shock, lung edema, psoriasis, adult respiratory distress syndrome, pain including dental pain, and aggregation of platelets.
    Type: Grant
    Filed: June 12, 1991
    Date of Patent: July 21, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Donald W. Graham, John C. Chabala, Tesfaye Biftu, Michael N. Chang, Yuan-Ching P. Chiang, Shu S. Yang, Kathryn L. Thompson
  • Patent number: 5120729
    Abstract: This application relates to compounds of formula (I), which are useful as antihypercholesterolemic agents.
    Type: Grant
    Filed: June 20, 1990
    Date of Patent: June 9, 1992
    Assignee: Merck & Co., Inc.
    Inventors: John C. Chabala, Michael N. Chang, Yuan-Ching P. Chiang, James V. Heck, Kathryn L. Thompson, Shu S. Yang
  • Patent number: 5047420
    Abstract: Novel 1,3-diaryl cyclopentanes of the following general formula were prepared. ##STR1## These compounds were found to have potent and specific PAF (Platelet Activating Factor) antagonistic activities and as such useful in the treatment or amelioration of various diseases or disorders mediate by the PAF, for example, hypotension, inflammation, nephritis, stroke and other cardiovascular disorders, asthma, allergic and skin diseases, peptic or stomach ulcer, shock, lung edema, psoriasis, adult respiratory distress syndrome, pain including dental pain, and aggregation of platelets.
    Type: Grant
    Filed: August 21, 1989
    Date of Patent: September 10, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Donald W. Graham, Tesfaye Biftu, John C. Chabala, Michael N. Chang, Yuan-Ching P. Chiang, Kathryn L. Thompson, Shu S. Yang
  • Patent number: 5010100
    Abstract: The present invention is directed to a specifically substituted tetrahydrofuran of the formula (I) ##STR1## wherein R.sup.4 is an alkylthio, alkylsulfinyl or alkylsulfonyl containing group, Y is an alkyl or substituted alkyl group and R.sup.6 is an alkoxy or a substituted alkoxy or alkyl group.
    Type: Grant
    Filed: June 8, 1989
    Date of Patent: April 23, 1991
    Assignee: Merck & Co. Inc.
    Inventors: Tesfaye Biftu, John C. Chabala, Robert L. Bugianesi, Mitree M. Ponpipom, Soumya P. Sahoo
  • Patent number: 4892869
    Abstract: Disclosed are 2-aza-substituted 1-carbadethiapen-2-em-3-carboxylic acids I, where the generic 2-aza group includes azido, acylamino, amino, alkylamino, dialkylamino, triazolyl, triazolinyl, aziridinyl, and their pharmaceutically acceptable salt, ester, anhydride and amide derivatives which are useful as antibiotics. Also disclosed are processes for the preparation of 1 from the known, appropriately substituted bicyclic keto ester II via the 2-azido central intermediate III: ##STR1## wherein R.sup.16 is H or CH.sub.3, preferably beta-methyl; R.sup.6, and R.sup.7 are independently hydrogen, linear, branched or cyclic C.sub.1 -C.sub.5 alkyl, which can be substituted with fluoro, hydroxy, protected hydroxy, sulfoxy, amino, protected amino, wherein R.sup.6 and R.sup.7 taken together can also be C.sub.2 -C.sub.4 alkylidene, similarly substituted; with the proviso that both R.sup.6 and R.sup.7 are not unsubstituted alkyl, R.sup.1 and R.sup.
    Type: Grant
    Filed: January 19, 1989
    Date of Patent: January 9, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Burton G. Christensen, Ronald W. Ratcliffe, John C. Chabala
  • Patent number: 4847271
    Abstract: The compounds of the following general structural formula (I) ##STR1## are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase inhibitors and useful as antihypercholesterolemic agents for the treatment of disease in which the inhibition of cholesterol biosynthesis would be useful, such as arteriosclerosis, hyperlipidemia and familial hypercholesterolemia.
    Type: Grant
    Filed: March 4, 1987
    Date of Patent: July 11, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John C. Chabala, Yuan-Ching P. Chiang, Michael N. Chang, Narindar M. Girotra, Donald W. Graham, Shu S. Yang
  • Patent number: 4833167
    Abstract: Disclosed are 2-aza-substituted 1-carbadethiapen-2-em-3-carboxylic acids I, where the generic 2-aza group includes azido, acylamino, amino, alkylamino, diaklylamino, triazolyl, triazolinyl, aziridinyl, and their pharmaceutically acceptable salt, ester, anhydride and amide derivatives which are useful as antibiotics. Also disclosed are processes for the preparation of I from the known, appropriately substituted bicyclic keto ester II via the 2-azido central intermediate III: ##STR1## wherein R.sup.16 is H or CH.sub.3, preferably beta-methyl; R.sup.6, and R.sup.7 are independently hydrogen, linear, branched or cyclic C.sub.1 -C.sub.5 alkyl, which can be substituted with fluoro, hydroxy, protected hydroxy, sulfoxy, amino, protected amino wherein R.sup.6 and R.sup.7 taken together can also be C.sub.2 -C.sub.4 alkylidene, similarly substituted; with the proviso that both R.sup.6 and R.sup.7 are not unsubstituted alkyl, R.sup.1 and R.sup.
    Type: Grant
    Filed: June 10, 1985
    Date of Patent: May 23, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Burton G. Christensen, John C. Chabala, Ronald W. Ratcliffe
  • Patent number: 4806564
    Abstract: The compounds of the following structural formula (I) ##STR1## are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase inhibitors and useful as antihypercholesterolemic agents for the treatmet of disease in which the inhibition of cholesterol biosynthesis would be useful, such as arteriosclerosis, hyperlipidemia and familial hypercholesterolemia.
    Type: Grant
    Filed: May 26, 1987
    Date of Patent: February 21, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John C. Chabala, Yuan-Ching P. Chiang, Michael N. Chang, Donald W. Graham, James V. Heck, Shu S. Yang
  • Patent number: 4783453
    Abstract: Disclosed are 2-aza-substituted 1-carbadethiapen-2-em-3-carboxylic acids I, where the generic 2-aza group includes azido, acylamino, amino, alkylamino, dialkylamino, triazolyl, triazolinyl, aziridinyl, and their pharmaceutically acceptable salt, ester, anhydride and amide derivatives which are useful as antibiotics. Also disclosed are processes for the preparation of I from the known, appropriately substituted bicyclic keto ester II via the 2-azido central intermediate III: ##STR1## wherein R.sup.16 is H or CH.sub.3, preferably beta-methyl; R.sup.6, and R.sup.7 are independently hydrogen, linear, branched or cyclic C.sub.1 -C.sub.5 alkyl, which can be substituted with fluoro, hydroxy, protected hydroxy, sulfoxy, amino, protected amino, wherein R.sup.6 and R.sup.7 taken together can also be C.sub.2 -C.sub.4 alkylidene, similarly substituted; with the proviso that both R.sup.6 and R.sup.7 are not unsubstituted alkyl, R.sup.1 and R.sup.
    Type: Grant
    Filed: September 8, 1987
    Date of Patent: November 8, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Burton G. Christensen, Ronald W. Ratcliffe, John C. Chabala
  • Patent number: 4782051
    Abstract: Disclosed are 2-aza-substituted 1-carbadethiapen-2-em-3-carboxylic acids I, where the generic 2-aza group includes azido, acylamino, amino, alkylamino, dialkylamino, trizolyl, triazolinyl, aziridinyl, and their pharmaceutically acceptable salt, ester, anhydride and amide derivatives which are useful as antibiotics. Also disclosed are processes for the preparation of I from the known, appropriately substituted bicyclic keto ester II via the 2-azido central intermediate III: ##STR1## wherein R.sup.16 is H or CH.sub.3, preferably beta-methyl; R.sup.6, and R.sup.7 are independently hydrogen, linear, branched or cyclic C.sub.1 -C.sub.5 alkyl, which can be substituted with fluoro, hydroxy, protected hydroxy, sulfoxy, amino, protected amino, wherein R.sup.6 and R.sup.7 taken together can also be C.sub.2 -C.sub.4 alkylidene, similarly substituted; with the proviso that both R.sup.6 and R.sup.7 are not unsubstituted alkyl, R.sup.1 and R.sup.
    Type: Grant
    Filed: August 17, 1987
    Date of Patent: November 1, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Burton G. Christensen, John C. Chabala, Ronald W. Ratcliffe
  • Patent number: 4751237
    Abstract: The compounds of the following general structural formula (I) ##STR1## wherein R is hydrogen or C.sub.1-3 alkyl and the tetrahydro analogs thereof, are 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) synthase inhibitors and useful as antihypercholesterolemic agents for the treatment of disease in which the inhibition of cholesterol biosynthesis would by useful, such as arteriosclerosis, hyperlipidemia and familial hypercholesterolemia.
    Type: Grant
    Filed: April 28, 1986
    Date of Patent: June 14, 1988
    Assignee: Merck & Co., Inc.
    Inventors: John C. Chabala, Arthur A. Patchett, Michael D. Greenspan
  • Patent number: 4659720
    Abstract: 5-Amino or substituted amino imidazoles are disclosed as having anticoccidial activity. The compounds are useful for controlling cecal and or intestinal coccidiosis when administered in minor quantitites to animals, in particular to poultry, usually in admixture with animal sustenance.
    Type: Grant
    Filed: November 16, 1983
    Date of Patent: April 21, 1987
    Assignee: Merck & Co., Inc.
    Inventors: John C. Chabala, Michael H. Fisher, Arthur A. Patchett
  • Patent number: 4590201
    Abstract: Novel 5-amino or substituted amino 1,2,3-triazoles are disclosed as having anticoccidial activity. The compounds are useful for controlling coccidiosis when administered in minor quantities to animals, in particular to poultry, usually in admixture with animal sustenance.
    Type: Grant
    Filed: February 2, 1984
    Date of Patent: May 20, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Richard J. Bochis, John C. Chabala, Michael H. Fisher
  • Patent number: RE32006
    Abstract: Derivatives of the C-076 compounds are disclosed wherein the 13-position is unsubstituted or substituted by a halogen atom. The compounds are prepared by removing the glycosyl groups on the 13-position of the C-076 compounds isolated from the fermentation broth of Streptomyces avermitilis. This is followed by substitution of the 13-hydroxy group with a halogen, and subsequent removal of the halogen. The disclosed compounds are antiparasitic, anthelmintic, insecticidal and acaracidal agents.
    Type: Grant
    Filed: July 18, 1984
    Date of Patent: October 15, 1985
    Assignee: Merck & Co., Inc.
    Inventors: John C. Chabala, Michael H. Fisher, Helmut H. Mrozik
  • Patent number: RE32034
    Abstract: Derivatives of the C-076 compounds are disclosed wherein the 13-position is unsubstituted. The compounds are prepared by removing the glycosyl groups on the 13-position of the C-076 compounds isolated from the fermentation broth of Streptomyces avermitilis, followed by halogenation and subsequent removal of the halogen. The disclosed compounds are antiparasitic, anthelmintic, insecticidal and acaricidal agents.
    Type: Grant
    Filed: July 18, 1984
    Date of Patent: November 19, 1985
    Assignee: Merck & Co., Inc.
    Inventors: John C. Chabala, Michael H. Fisher, Helmut H. Mrozik